2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional study
Zeybek B, Webster E, Pogosian N, Tymon-Rosario J, Balch A, Altwerger G, Clark M, Menderes G, Huang G, Azodi M, Ratner ES, Schwartz PE, Santin AD, Andikyan V. Financial toxicity in patients with gynecologic malignancies: a cross sectional study. Journal Of Gynecologic Oncology 2021, 32: e87. PMID: 34431257, PMCID: PMC8550931, DOI: 10.3802/jgo.2021.32.e87.Peer-Reviewed Original ResearchMeSH KeywordsCost of IllnessCross-Sectional StudiesFemaleFinancial StressGenital Neoplasms, FemaleHumansSurveys and QuestionnairesConceptsCross-sectional studyGynecologic malignanciesFinancial toxicityPatient demographicsSectional studyMalignancy typeGynecologic oncology patientsOvarian cancer patientsPatient/diseaseCost of careFinancial burdenHigh financial burdenTreatment regimenHigh financial toxicityOncology patientsDisease characteristicsGynecologic cancerCancer careCancer patientsRisk factorsClinical trialsCOST scoreMedian COST scorePatientsSignificant burden
2019
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers
Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Gynecologic Oncology 2019, 153: 158-164. PMID: 30630630, PMCID: PMC6430698, DOI: 10.1016/j.ygyno.2019.01.002.Peer-Reviewed Original ResearchMeSH KeywordsAdultAfatinibAgedAnimalsAntineoplastic AgentsCell Line, TumorClass I Phosphatidylinositol 3-KinasesClass Ia Phosphatidylinositol 3-KinaseDrug Resistance, NeoplasmFemaleGenital Neoplasms, FemaleHumansMiceMice, SCIDMiddle AgedMutationPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsReceptor, ErbB-2TransfectionXenograft Model Antitumor AssaysConceptsHER2/neuAKT/mTOR pathwayPIK3CA mutationsMTOR pathwayActivity of afatinibEffect of afatinibPI3K/AKT/mTOR pathwayPotential mechanismsPIK3CA/AKT/mTOR pathwayRapid tumor growthGreater compensatory increasePI3K mutationsAmplification/mutationOncogenic PIK3CA mutationsAfatinib exposurePIK3CA H1047RGynecological cancerClinical trialsMTOR inhibitorsAfatinibTumor growthCompensatory increasePhosphorylated Akt proteinPIK3CA geneC-erb
2009
Extragenital adenosarcoma: A case report, review of the literature, and management discussion
Huang GS, Arend RC, Sakaris A, Hebert TM, Goldberg GL. Extragenital adenosarcoma: A case report, review of the literature, and management discussion. Gynecologic Oncology 2009, 115: 472-475. PMID: 19712965, PMCID: PMC4451226, DOI: 10.1016/j.ygyno.2009.07.033.Peer-Reviewed Case Reports and Technical NotesConceptsSarcomatous overgrowthLiposomal doxorubicinHigh-grade bowel obstructionMixed epithelial-mesenchymal tumorsComplete clinical responseInitial cytoreductive surgeryCompletion of chemotherapyFavorable prognostic factorAggressive clinical behaviorCoexistent endometriosisConcurrent endometriosisBowel obstructionCytoreductive surgeryClinical responseExtragenital sitesPrognostic factorsCase reportClinical behaviorSecond surgeryMüllerian adenosarcomaRare caseAdenosarcomaEndometriosisChemotherapySurgery
2004
Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age
O'Hanlan KA, Huang GS, Lopez L, Garnier AC. Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age. Gynecologic Oncology 2004, 95: 196-203. PMID: 15385132, DOI: 10.1016/j.ygyno.2004.07.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overFemaleGenital Neoplasms, FemaleHumansHysterectomyLaparoscopyMiddle AgedRetrospective StudiesTreatment OutcomeConceptsTotal laparoscopic hysterectomyBody mass indexOvarian carcinomaAdhesive bowel obstructionEarly ovarian carcinomaFamilial ovarian carcinomaMean blood lossOverall complication rateComplex pelvic massChi-square testUrologic complicationsBowel obstructionHospital stayComplication rateBlood lossCervical dysplasiaEndometrial neoplasiaLaparoscopic hysterectomyMass indexVaginal carcinomaPelvic massPreoperative diagnosisSurgical durationSurgical outcomesOncological indications